Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incannex Healthcare Inc. - Common Stock (NQ: IXHL )

1.800 UNCHANGED
Streaming Delayed Price Updated: 10:56 AM EST, Jan 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Incannex Healthcare Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Psyched: Millions From Institutional Investor And Fed Funding For Research, M&As, Women Veterans And More
Major Investor Commits $30 Million To Psychedelics Funding 
Via Benzinga
Why A National Cannabis Organization Sacked Half Its Staff, CEO Turnovers And More Exec Changes
NCIA Sacks Half Of Its Team To Increase Financial Strength 
Via Benzinga
May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances
Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May. 
Via Talk Markets
Incannex welcomes world-leading psychedelics experts to advisory board
Incannex welcomes world-leading psychedelics experts to advisory board 
Via News Direct
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application... 
Via Benzinga
Why Incannex Healthcare Shares Are Gaining Today
Via Benzinga
Incannex Healthcare Has World's Largest Pipeline Of Psychedelic Products
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. 
Via Talk Markets
Psychedelic Therapies Soon Available In Australia Via Incannex Healthcare And Subsidiary
Biotech giant Incannex Healthcare Ltd (NASDAQ: IXHL) shared a business presentation of its newly formed psychedelic-assisted therapies subsidiary company, Psychennex Pty Ltd. 
Via Benzinga
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations 
Via Benzinga
Incannex Stock Trading Higher On Entering A Lease For First Psychedelic-Assisted Psychotherapy Clinic
Incannex Healthcare Ltd (NASDAQ: IXHL) (ASX:IHL) announced that its subsidiary company, Clarion Clinics Group Pty Ltd, has entered a lease for riverfront premises in Abbottsford, Melbourne. 
Via Benzinga
Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A
Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A 
Via News Direct
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued 
Via Benzinga
April Psychedelic Drug Stocks Recap: The Ups And Downs
Via Talk Markets
New Clinical MDMA And Psilocybin Batches Head To Flourishing Psychedelics Market
Psychedelics developer PharmAla Biotech continues to provide its Good Manufacturing Practices (GMP)-compliant psychedelics to Australian-based businesses developing clinical trials and, soon, actual... 
Via Benzinga
Largest Psychedelic Stocks -3.4% In March
The munKNEE Psychedelic Drug Stocks Index was down 3.4% in March but is still +1.2% YTD. The best news is the continuing high price targets being set by analysts. 
Via Talk Markets
Cannabis Category Performances Ranged From +8.6% To -7.0% This Week
The 5 categories in the cannabis sector perform quite differently from each other and this week was a prime example. 
Via Talk Markets
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered 
Via Benzinga
Incannex Healthcare Prepares To Launch Psychedelics Clinics Via New Subsidiary
Australia-based biopharma giant Incannex Healthcare Ltd. (NASDAQ: IXHL) has plans to commercialize its psychedelic-assisted psychotherapy business through a new subsidiary venture under the leadership... 
Via Benzinga
Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder
Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions. 
Via Benzinga
Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers ThermoGenesis Holdings, Inc. (NASDAQ: THMO) shares jumped 80% to $3.7820 after the company announced the roll out of ReadyStart cGMP Suites for early-stage cell and gene-therapy companies. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
All 5 Cannabis Categories Down Last Week; Only 1 Is UP YTD
The 5 categories in the cannabis sector perform quite differently from each other. Only 1 is up YTD. 
Via Talk Markets
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... 
Via Benzinga
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.   
Via Benzinga
Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use
Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use 
Via News Direct
Incannex Engages Catalent For Development And Manufacture Of Psilocybin Drug For Clinical Trials
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, has... 
Via Benzinga
Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial
Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial 
Via News Direct
Incannex Starts Phase 2 Clinical Trial Of CBD-Based Drug For Use In Treatment Of Rheumatoid Arthritis
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has commenced a phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug IHL-675A in patients... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.